Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEA 2180 BR in COPD
NCT00128440Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bea 2180 in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Trough forced expiratory volume in one second response at 24 hours and Forced expiratory volume in one second area under the curve from 0 to 6 hours. Started Aug 2005; status: completed.
02
Drugs
bea 2180
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00128440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128440.